Cargando…

Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer

Taxane based chemotherapy is the standard of care treatment in castration resistant prostate cancer (CRPC). There is convincing evidence that taxane therapy affects androgen receptor (AR) but the exact mechanisms have to be further elucidated. Our studies identified c-jun as a crucial key player whi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tinzl, Martina, Chen, Binshen, Chen, Shao-Yong, Semenas, Julius, Abrahamsson, Per-Anders, Dizeyi, Nishtman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832643/ https://www.ncbi.nlm.nih.gov/pubmed/24260253 http://dx.doi.org/10.1371/journal.pone.0079573

Ejemplares similares

Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer
por: Tinzl, Martina, et al.
Publicado: (2018)

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
por: Semenas, Julius, et al.
Publicado: (2013)

Multiple Cellular Mechanisms Related to Cyclin A1 in Prostate Cancer Invasion and Metastasis
por: Wegiel, Barbara, et al.
Publicado: (2008)

Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells
por: Sarwar, Martuza, et al.
Publicado: (2016)

Influence of Melatonin on the Proliferative and Apoptotic Responses of the Prostate under Normal and Hyperglycemic Conditions
por: Gobbo, Marina G., et al.
Publicado: (2015)

The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1α/pAKT in prostate cancer
por: Larsson, Per, et al.
Publicado: (2019)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
por: Abrahamsson, Per-Anders
Publicado: (2017)

ERG induces taxane resistance in castration-resistant prostate cancer
por: Galletti, Giuseppe, et al.
Publicado: (2014)

Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer
por: Shan, Xiaochuan, et al.
Publicado: (2015)

Replication study: androgen receptor splice variants determine taxane sensitivity in prostate cancer
por: Shan, Xiaochuan, et al.
Publicado: (2018)

Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
por: Bumbaca, Brandon, et al.
Publicado: (2018)

Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy
por: Shimizu, Yasuomi, et al.
Publicado: (2018)

Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
por: Jiménez, Natalia, et al.
Publicado: (2020)

Taxane-based Chemotherapy Induced Androgen Receptor Splice Variant 7 in Patients with Castration-Resistant Prostate Cancer: A Tissue-based Analysis
por: Shim, Myungsun, et al.
Publicado: (2019)

Impact of taxanes on androgen receptor signaling
por: Bai, Shanshan, et al.
Publicado: (2019)

Targeting Taxanes to Castration-Resistant Prostate Cancer Cells by Nanobubbles and Extracorporeal Shock Waves
por: Marano, Francesca, et al.
Publicado: (2016)

Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer
por: Sarwar, Sadia, et al.
Publicado: (2022)

A 23‐Gene Classifier urine test for prostate cancer prognosis
por: Guo, Jinan, et al.
Publicado: (2021)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Francini, Edoardo, et al.
Publicado: (2021)

Non-invasive Urine Test for Molecular Classification of Clinical Significance in Newly Diagnosed Prostate Cancer Patients
por: Guo, Jinan, et al.
Publicado: (2021)

Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up
por: Johnson, Heather, et al.
Publicado: (2020)

The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer
por: Gunter, Jennifer H., et al.
Publicado: (2012)

Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects
por: Abidi, Afroz
Publicado: (2013)

Predictive value of stathmin-1 and osteopontin expression for taxan resistance in metastatic castrate-resistant prostate cancer
por: Aksoy, Asude, et al.
Publicado: (2017)

Exosomes Promote the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manner Through Up-Regulating the Heme Oxygenase-1
por: Zhang, Yiming, et al.
Publicado: (2021)

Roles of autophagy in androgen-induced benign prostatic hyperplasia in castrated rats
por: Liu, Rong-Fu, et al.
Publicado: (2018)

Epithelial and Stromal Characteristics of Primary Tumors Predict the Bone Metastatic Subtype of Prostate Cancer and Patient Survival after Androgen-Deprivation Therapy
por: Wikström, Pernilla, et al.
Publicado: (2022)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

The expression of AURKA is androgen regulated in castration-resistant prostate cancer
por: Kivinummi, Kati, et al.
Publicado: (2017)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Effects of Black Raspberries and Their Ellagic Acid and Anthocyanin Constituents on Taxane Chemotherapy of Castration-Resistant Prostate Cancer Cells
por: Eskra, Jillian N., et al.
Publicado: (2019)

Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes
por: Marín-Aguilera, Mercedes, et al.
Publicado: (2021)

Androgen deprivation therapy and side effects: are GnRH antagonists safer?
por: Freedland, Stephen J, et al.
Publicado: (2020)

Co-Targeting ErbB Receptors and the PI3K/AKT Axis in Androgen-Independent Taxane-Sensitive and Taxane-Resistant Human Prostate Cancer Cells
por: Adediran, Samusi, et al.
Publicado: (2022)

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants
por: Shiota, Masaki, et al.
Publicado: (2018)

Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
por: Su, Christopher T., et al.
Publicado: (2022)

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
por: Perner, Sven, et al.
Publicado: (2015)

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer
por: Pollock, Julie A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p95fcdke65lk9oqsdchqb542k3